Next Article in Journal
CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
Next Article in Special Issue
A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting
Previous Article in Journal
Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas
Previous Article in Special Issue
Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma
Article

DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer

1
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau, China
2
Institute of Molecular and Cell Biology, A*STAR, Singapore 138673, Singapore
3
Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Londonderry BT47 6SB, UK
4
Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
5
Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, College of Life Sciences, Fujian Normal University, Fuzhou 350117, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2018, 10(9), 282; https://doi.org/10.3390/cancers10090282
Received: 27 June 2018 / Revised: 17 August 2018 / Accepted: 20 August 2018 / Published: 22 August 2018
(This article belongs to the Special Issue Cancer Biomarkers)
Breast cancer is one of the most common malignancies in women worldwide. In breast cancer, the cell proliferation rate is known to influence the cancer malignancy. Recent studies have shown that DNA replication initiation/licensing factors are involved in cancer cell proliferation as well as cancer cell migration and invasion. Licensing factors have also been reported as important prognostic markers in lung, prostrate, and bladder cancers. Here, we studied the role of MCM10, a novel licensing factor, in breast cancer progression. From the public database, NCBI, we investigated six independent breast cancer patient cohorts, totaling 1283 patients. We observed a significant association between high MCM10 mRNA expression with tumor grading and patients’ survival time. Most importantly, using breast cancer cohorts with available treatment information, we also demonstrated that a high level of MCM10 is associated with a better response to conventional treatment. Similarly, in in vitro studies, the expression level of MCM10 in breast cancer cell lines is significantly higher compared to paired normal breast epithelium cells. Knockdown of MCM10 expression in the cancer cell line showed significantly decreased tumorigenic properties such as cell proliferation, migration and anchorage independence. The MCF7 breast cancer cell line, after MCM10 expression knockdown, showed significantly decreased tumorigenic properties such as cell proliferation, migration, and anchorage independent growth. Mechanistically, MCM10 expression is observed to be regulated by an Estrogen Receptor (ER) signaling pathway, where its expression is suppressed by the inhibition of the ER or serum withdrawal. Our results suggest that MCM10 plays an important role in breast cancer progression and is a potential prognostic/predictive biomarker and therapeutic target for breast cancer patients. View Full-Text
Keywords: MCM10; breast cancer; knockdown; overexpression; proliferation; survival MCM10; breast cancer; knockdown; overexpression; proliferation; survival
Show Figures

Figure 1

MDPI and ACS Style

Mahadevappa, R.; Neves, H.; Yuen, S.M.; Jameel, M.; Bai, Y.; Yuen, H.-F.; Zhang, S.-D.; Zhu, Y.; Lin, Y.; Kwok, H.F. DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer. Cancers 2018, 10, 282. https://doi.org/10.3390/cancers10090282

AMA Style

Mahadevappa R, Neves H, Yuen SM, Jameel M, Bai Y, Yuen H-F, Zhang S-D, Zhu Y, Lin Y, Kwok HF. DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer. Cancers. 2018; 10(9):282. https://doi.org/10.3390/cancers10090282

Chicago/Turabian Style

Mahadevappa, Ravikiran, Henrique Neves, Shun M. Yuen, Muhammad Jameel, Yuchen Bai, Hiu-Fung Yuen, Shu-Dong Zhang, Youzhi Zhu, Yao Lin, and Hang F. Kwok. 2018. "DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer" Cancers 10, no. 9: 282. https://doi.org/10.3390/cancers10090282

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop